LKC Technologies unveils enhanced PhNR protocol for improved, objective glaucoma testing and tracking

,

According to the company, the protocol enhancement for the RETeval Device marks an important step in mitigating vision loss from glaucoma.

To mark Glaucoma Awareness Month, LKC Technologies is releasing an enhanced PhNR protocol for its RETeval Device, a portable full-field ERG non-mydriatic testing device that is FDA approved.

Glaucoma is one of the leading causes of blindness worldwide. Early detection and ongoing tracking of glaucoma through typical means is often hampered by the subjectivity of perimetry and the indeterminacy of imaging, par Electroretinographic testing of the Photopic Negative Response (PhNR) has long been established as an objective tool to assess retinal ganglion cell function to detect and track diseases like glaucoma.

According to the company, the protocol enhancement for the RETeval Device marks an important step in mitigating vision loss from glaucoma. The algorithm provides a 4-times improvement in test/retest variability, and a normative reference range that's 1.7-times narrower. The result is a more sensitive tool aiding in the detection of abnormal ganglion cell function.

"This new algorithm provides clinicians with the results needed to unleash the power of PhNR in the clinical assessment of patients, particularly for glaucoma.” Jim Datovech, president of LKC, said in a statement. “We are proud to be making our mark by aiding detection options in a practical way for the fullest range of eye care professionals.”

The company noted that the RETeval, which debuted in 2014, has been put to practical use of ERG in a clinical setting. It comes with a large reference data set for straightforward interpretation. Furthermore, it requires no corneal contact, dilation, or anesthetics